Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description

Aim: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies sh...

Descripción completa

Detalles Bibliográficos
Autores: Pina-Camacho, L, Diaz-Caneja, CM, Saiz, PA, Bobes, J, Corripio, I, Grasa, E, Rodriguez-Jimenez, R, Fernandez, M, Sanjuan, J, Garcia-Lopez, A, Tapia-Casellas, C, Alvarez-Blazquez, M, Fraguas, D, Mitjans, M, Arias, B, Arango, C
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2014
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p8858
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8858
Access Level:acceso abierto
Palabra clave:Antipsychotic Agents
Weight Gain
Metabolic Syndrome
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Descripción
Sumario:Aim: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-individual genetic differences produce varying degrees of vulnerability to the different SGA-induced side effects. The Second-generation antipsychotic Long-term treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental and genetic factors that explain inter-individual differences in weight gain and metabolic changes in drug-naive patients after six months of treatment with SGAs. Materials and methods: The SLIM study is a multicenter, observational, six-month pharmacogenetic study where a cohort of 307 drug-naive paediatric and adult patients (age range 8.8-90.1 years) and a cohort of 150 age- and sex- matched healthy controls (7.8-73.2 years) were recruited. Results: This paper describes the rationale, objectives and design of the study and provides a description of the sample at baseline. Conclusions: Results from the SUM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment. (C) 2014 SEP y SEPB. Published by Elsevier Espana, S.L.U. All rights reserved.

Similares en LA Referencia